Brief: Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results
13/01/2026 22:24
Jan 13 (Reuters) - TG Therapeutics Inc TGTX.O: TG THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUE AND 2026 REVENUE GUIDANCE AND ANTICIPATED DEVELOPMENT MILESTONES TG THERAPEUTICS INC - 2026 GLOBAL REVENUE TARGET $875-900 MILLION, BRIUMVI U.S. $825-850 MILLION TG THERAPEUTICS INC - PHASE 1 AZER-CEL DATA IN PROGRESSIVE MS EXPECTED SECOND HALF 2026 Source text: ID:nGNX6BPwLK Further company coverage: TGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj